Skip to main content
Home > BioCentury on BioBusiness > Finance/Investment

Chronological Index of : Finance

 Current Issue
  • Figure: Money Raised in 2016

    Frazier's GAIN Money Raised in 2016 Last week, the biotech industry raised $411 million, bringing to $8.3 billion the total raised year-to-date. In 2015, a total of $110.5 billion was raised, including $56.6 …

    Published on 4/4/2016
  • Figure: Among the bulls

    Fundamental reset Among the bulls The most recent biotech bull run, which followed the 2008-09 financial crisis, was the longest (333 weeks) and best performing (+543%) of the last five bull markets. Because of …

    Published on 4/4/2016
  • Figure: Biotech fund flows

    Fundamental reset Biotech fund flows Biotech funds saw net outflows of $3.2 billion in 1Q16, although there were signs of life in the quarter's final month. In 1Q15, net inflows were $4.1 billion. The March fund …

    Published on 4/4/2016
  • Table: Follow-on performance

    Fundamental reset Follow-on performance Follow-on activity tailed off in the last two months of the quarter, with about half of the 1Q offerings closing in February and March. For the quarter, $1.8 billion was …

    Published on 4/4/2016
  • Table: IPO performance

    Fundamental reset IPO performance While the number of IPOs dropped off last quarter, the group of newly public companies managed to post a median gain of 18%, led by a 149% rise in the market value of Korean …

    Published on 4/4/2016
  • Table: IPO queue

    Fundamental reset IPO queue At least seven companies have announced plans to go public since the start of 1Q16, bringing the IPO queue to at least 23. Unless noted, companies are seeking to list on NASDAQ. Filings…

    Published on 4/4/2016
  • Fundamental reset

    How biotech companies, bankers and buysiders will adjust to a new base in 2Q16

    With a floor nearly established and sector fundamentals unchanged, bio-bankers and buysiders agree it's a good time to put money to work.

    Published on 4/4/2016
  • Frazier's GAIN

    How GAIN Act, management teams led Frazier to back two big antibiotic A rounds

    Finance Ebb & Flow Frazier's GAIN Figure: Money Raised in 2016 The benefits of the Generating Antibiotic Incentives Now Act, coupled with the ability to back repeat entrepreneurs, prompted Frazier Healthcare …

    Published on 4/4/2016
  • Ample opportunity

    Investors' top names, milestones and meetings in 2Q16

    Event-driven buysiders have a full plate of late-stage milestones in 2Q16.

    Published on 4/4/2016
  • Figure: London vs. Europe

    None shall pass London vs. Europe The BioCentury Europe index is back to where it started last September, after gaining 18% in 4Q15 and then declining 11% last quarter. Seventeen of 19 continental European …

    Published on 4/4/2016
  • Figure: Price-to-earnings: BT vs. RX

    None shall pass Price-to-earnings: BT vs. RX Biotech's average P/E ended 1Q at 20.8, down 14% from 4Q15 and 17% from a year ago. Two companies — rare disease play Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and …

    Published on 4/4/2016
  • Figure: Results by market cap

    None shall pass Results by market cap All market cap segments fell more than 12% in 1Q. Companies valued at $5 billion or more fell by a median of 16%, led by a 74% decline in the share price of Valeant …

    Published on 4/4/2016
  • Table: 1Q approvals

    None shall pass 1Q approvals Selected 1Q approvals. Company Approval Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Japan approves Kanuma sebelipase alfa to treat lysosomal acid lipase deficiency (LAL-D) Amgen …

    Published on 4/4/2016
  • Table: Index performance

    None shall pass Index performance Index 1Q16 DJIA 1% S&P 500 1% NASDAQ Composite -3% BioCentury London -7% NYSE Arca Pharmaceutical -9% BioCentury Europe -11% NYSE Arca Biotechnology -22% NASDAQ …

    Published on 4/4/2016
  • Table: Restructuring watch

    None shall pass Restructuring watch At least nine companies reported workforce reductions in the first quarter compared to at least five in the same period last year. Table below is sorted by date ascending. All …

    Published on 4/4/2016
  • Medicxi's platform exception

    Why Medicxi made Gadeta an exception to the VC's asset-centric model

    Finance Medicxi's platform exception Medicxi Ventures spurned its typical asset-centric model for the second time this month because the firm thought Gadeta B.V.'s T cell receptor platform was too good an …

    Published on 4/4/2016
  • Padded coffers

    How Atlas is applying lessons from Padlock, CoStim exits in new fund

    Ebb & Flow Ebb & Flow Padded coffers Figure: Money Raised in 2016 It's still early days for Atlas Venture's first life sciences-only fund, but don't be surprised if the firm starts putting more money to work …

    Published on 3/28/2016
  • Figure: Money Raised in 2016

    Padded coffers Money Raised in 2016 Last week, the biotech industry raised $452 million, bringing to $7.8 billion the total raised year-to-date. In 2015, a total of $110.5 billion was raised, including $56.6 …

    Published on 3/28/2016
  • Analyze this

    Why Chi-Med listed on NASDAQ

    Ebb & Flow Analyze this With a host of clinical data events coming in 12-18 months, Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) sought a U.S. listing to gain access to specialists and analysts who can help …

    Published on 3/28/2016
  • Back in the game

    Why Gimv came off the sidelines for Topas' series A

    Ebb & Flow Back in the game After spending the last few years exiting many of its biotech portfolio companies, Gimv is again putting capital to work in the space. The firm is picking up where it left off with a bet…

    Published on 3/28/2016
  • Figure: Bear country

    Bottoms up? Bear country The current biotech bear market is among the sharpest and longest downturns the industry has seen. The chart below shows the BioCentury 100 index during the past five bear markets, …

    Published on 3/21/2016
  • Figure: Sliding shorts

    Bottoms up? Sliding shorts The short interest on the iShares NASDAQ Biotechnology ETF (IBB) is at its lowest level over the past 12 months. Short interest peaked right after Hillary Clinton's September 2015 tweet …

    Published on 3/21/2016
  • Bottoms up?

    Debating whether biotech has bottomed out

    Long-term investors are willing to risk that the downturn could deepen to start building positions in names previously deemed too expensive.

    Published on 3/21/2016
  • Stress test

    How Frazier formed Outpost around a Takeda asset

    Finance Stress test Frazier Healthcare's latest round of asset sleuthing led the firm to a molecule from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) for stress urinary incontinence, which has no approved drugs in …

    Published on 3/21/2016
  • Figure: Money Raised in 2016

    Multiples in Korea Money Raised in 2016 Last week, the biotech industry raised $599 million, bringing to $7.4 billion the total raised year-to-date. In 2015, a total of $110.4 billion was raised, including $56.6 …

    Published on 3/21/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993